Non-small cell lung cancer

News

AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.

News

BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.

News

New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.

News

Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.

News

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.

News

Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.